Literature DB >> 26620210

Long-term outcome after treatment of pulmonary atresia with ventricular septal defect: nationwide study of 109 patients born in 1970-2007.

Anu K Kaskinen1, Juha-Matti Happonen2, Ilkka P Mattila2, Olli M Pitkänen2.   

Abstract

OBJECTIVES: Treatment of pulmonary atresia with ventricular septal defect (PA + VSD) has evolved during recent decades, but it still remains challenging. This study evaluated 41-year experience of outcome, survival and treatment of PA + VSD patients.
METHODS: Patient records and angiograms of 109 patients with PA + VSD born in Finland between 1970 and 2007, and treated at the Children's Hospital, Helsinki University Central Hospital, were retrospectively analysed in this nationwide study.
RESULTS: Of the 109 patients, 66 (61%) had simple PA + VSD without major aortopulmonary collateral arteries (MAPCAs). Although we observed no difference in overall survival between those with or without MAPCAs, the patients without MAPCAs had better probability to achieve repair (64 vs 28%, P < 0.0003). Only 3 patients were treated by compassionate care. Overall survival was affected by the size of true central pulmonary arteries on the first angiogram (P = 0.001) and whether repair was achieved (P < 0.0001). After successful repair, the survival rate was 93% at 1 year, 91% from the second year, and functional capacity as assessed by New York Heart Association (NYHA) I-II remained in 85% of patients alive at the end of follow-up. Palliated patients at 1, 5, 10 and 20 years of age had Kaplan-Meier estimated survival rates of 55, 42, 34 and 20%, respectively. Patients who underwent repair attempts but were left palliated with right ventricle (RV)-pulmonary artery connection and septal fenestration had better survival than the rest of the palliated patients (P = 0.001). Further, the McGoon index improved after implementation of a systemic-pulmonary artery shunt in the overall PA + VSD population (P < 0.0001).
CONCLUSIONS: These findings show that achievement of repair and initial size of true central pulmonary arteries affect survival of patients with PA + VSD. Although the overall survival of patients with MAPCAs showed no difference compared with simple PA + VSD patients, they had a higher risk of remaining palliated. However, palliative surgery may have a role in treatment of PA + VSD because the size of pulmonary arteries increased after placement of systemic-pulmonary artery shunt. In addition, subtotal repair by a RV-pulmonary artery connection and septal fenestration improved survival over extracardiac palliation.
© The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Congenital heart defect; Incidence; Late results; McGoon index; Mortality; Pulmonary blood supply

Mesh:

Year:  2015        PMID: 26620210     DOI: 10.1093/ejcts/ezv404

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  3 in total

1.  Anatomy of the retro-oesophageal major aortopulmonary collateral arteries in patients with pulmonary atresia with ventricular septal defect: results from preoperative CTA.

Authors:  Qianjun Jia; Jianzheng Cen; Jinglei Li; Jian Zhuang; Hui Liu; Qun Zhang; Xiaoqing Liu; Meiping Huang; Changhong Liang
Journal:  Eur Radiol       Date:  2018-01-05       Impact factor: 5.315

Review 2.  Comparison of staged repair versus single-stage complete repair for pulmonary atresia with ventricular septal defect: A systematic review and meta-analysis.

Authors:  Huzeifa Elhedai; Mustafa Mohamed; Salma Saeed S Mohammed; Khalid H H Mustafa; Mohamed Hassan A Seedahmed; Ali Yasen Y Mohamedahmed
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-11-18

3.  Current era outcomes of pulmonary atresia with ventricular septal defect: A single center cohort in Thailand.

Authors:  Kanthalas Lertsakulpiriya; Chodchanok Vijarnsorn; Prakul Chanthong; Paweena Chungsomprasong; Supaluck Kanjanauthai; Kritvikrom Durongpisitkul; Jarupim Soongswang; Thaworn Subtaweesin; Somchai Sriyoschati
Journal:  Sci Rep       Date:  2020-03-20       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.